Home > Healthcare > Medical Devices > Diagnostic Devices > Cancer Biopsy Market

Cancer Biopsy Market Trends

Report ID: GMI10995
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Cancer Biopsy Market Trends

The rising prevalence of cancer significantly drives the market, as increased cancer cases heighten the demand for precise diagnostic tools. This surge in cancer incidence leads to a growing need for various biopsy techniques for early and accurate detection and treatment planning.

For instance, according to the International Agency for Research on Cancer (IARC) 2022 report, among 20 million new cancer cases worldwide, lung cancer and female breast cancer are the most common, representing 12.4% and 11.6% of cases, respectively. They are followed by colorectal cancer (9.6%), prostate cancer (7.3%), and stomach cancer (4.9%). This increasing incidence represents a large potential patient population requiring biopsies for diagnosis and treatment, bolstering market demand. This leads to greater adoption of various biopsy techniques, such as fine needle aspiration (FNA) and core needle biopsy (CNB), driving market growth.
Additionally, the need for ongoing monitoring and assessment in cancer patients further expands the market, as repeat biopsies become essential for effective treatment management.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cancer biopsy market size was USD 21.5 billion in 2023 and is expected to register 8.4% CAGR from 2024-2032 due to increasing prevalence of cancer and advancements in cancer diagnostic technologies, including biopsies worldwide.

Cancer biopsy industry from the tissue biopsy segment is expected to register 8.3% CAGR from 2024-2032 due to its preference as the gold standard for cancer diagnosis, providing highly accurate and reliable results.

The U.S. cancer biopsy industry is expected to reach USD 18 billion by 2032 due to advanced healthcare infrastructure, significant investment in research and development, and the presence of leading medical device companies in the Country.

ANGLE plc, Devicor Medical Products, Inc., GRAIL, Inc., Hologic, Inc., Illumina, Inc., IZI Medical Products, Lucence Health Inc., Myriad Genetics, Inc., Oncimmune Holdings PLC, Personal Genome Diagnostics Inc., and QIAGEN N.V., are some of the major cancer biopsy companies worldwide.